Form D · Biotechnology
Brava Diagnostics, Inc.
Boulder, CO · CIK 0001758829
Offering snapshot reported Sep 13, 2019 · SEC filing
- Reported sold
- $250K Offering amount: $1.5M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 29, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 13, 2019 | Initial | $250,000 | No comparison | 3 | SEC filing |
| Nov 16, 2018 | Initial | $4,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-348814
Convertible promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion
Source: Form D, filed Sep 13, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Byron Hewett | Director, Executive, Promoter |
| Carrie Mulherin | Promoter |
| Chris Myatt | Director |
| David Okrongly | Promoter |
| Robert Silverman | Director, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5603 Arapahoe Avenue Suite 1
Boulder, CO, 80303
Boulder, CO, 80303